Epigral Ltd Stock Falls to 52-Week Low of Rs 822.05 Amid Continued Downtrend

Recent Price Movement and Market Context

On 2 March 2026, Epigral Ltd’s share price opened sharply lower with a gap down of -7.93%, reaching an intraday low of Rs.822.05. This represents a day change of -4.16%, underperforming its Specialty Chemicals sector by 3.2%. The stock has been on a consistent decline for the past five trading sessions, losing a cumulative -11.09% over this period. Notably, Epigral is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a persistent bearish momentum.

In contrast, the broader market index, Sensex, despite opening 2,743.46 points lower, managed a partial recovery of 1,197.17 points to trade at 79,740.90, down 1.9% on the day. The Sensex remains below its 50-day moving average, although the 50DMA is positioned above the 200DMA, indicating mixed technical signals for the market overall.

Over the last year, Epigral Ltd’s stock has declined by 47.22%, a stark contrast to the Sensex’s positive return of 8.92% during the same period. The stock’s 52-week high was Rs.2,114.30, highlighting the extent of the recent correction.

Financial Performance and Profitability Trends

Epigral Ltd’s financial results have shown signs of strain in recent quarters. The company reported a quarterly Profit After Tax (PAT) of Rs.39.11 crores, which represents a decline of 61.1% compared to the average of the previous four quarters. Additionally, the Profit Before Depreciation, Interest, and Taxes (PBDIT) for the quarter stood at Rs.102.74 crores, marking the lowest level recorded in recent periods.

Interest expenses for the nine months ended December 2025 rose sharply by 43.93% to Rs.56.16 crores, indicating increased financing costs. This rise in interest burden has weighed on net profitability and overall earnings quality.

Over the last five years, the company’s operating profit has grown at a modest annual rate of 5.77%, which is considered subdued relative to sector peers and broader market expectations. This slow growth trajectory has contributed to the stock’s underperformance over the medium and long term.

Valuation and Efficiency Metrics

Despite the recent price weakness, Epigral Ltd exhibits certain strengths in operational efficiency and capital utilisation. The company’s Return on Capital Employed (ROCE) stands at a robust 23.19%, reflecting effective management of capital resources. Furthermore, the Debt to EBITDA ratio is a conservative 1.34 times, indicating a manageable debt load relative to earnings before interest, taxes, depreciation, and amortisation.

Valuation metrics also suggest the stock is trading at a discount compared to its peers’ historical averages. The Enterprise Value to Capital Employed ratio is 1.7, which is considered very attractive within the Specialty Chemicals sector. However, this valuation discount has not translated into positive returns, as profits have declined by 2.9% over the past year.

Shareholding and Market Grade

The majority shareholding in Epigral Ltd remains with the promoters, maintaining a stable ownership structure. The company’s Mojo Score currently stands at 31.0, with a Mojo Grade of Sell, upgraded from a previous Strong Sell rating on 26 December 2025. The Market Capitalisation Grade is rated at 3, reflecting the company’s mid-tier market cap status within its sector.

Comparative Performance and Sector Positioning

Epigral Ltd’s stock has underperformed not only the Sensex but also the BSE500 index over multiple time frames, including the last three years, one year, and three months. This consistent underperformance highlights challenges in maintaining competitive growth and market positioning within the Specialty Chemicals sector.

The stock’s 52-week high of Rs.2,114.30 contrasts sharply with the current price level, underscoring the significant correction experienced over the past year. The sector itself has seen mixed performance, with some peers maintaining stronger growth and valuation metrics.

Summary of Key Metrics

To summarise, Epigral Ltd’s key financial and market metrics as of 2 March 2026 are:

• New 52-week low price: Rs.822.05
• One-year stock return: -47.22%
• Sensex one-year return: +8.92%
• Quarterly PAT: Rs.39.11 crores (-61.1% vs previous 4Q average)
• Quarterly PBDIT: Rs.102.74 crores (lowest recorded)
• Interest expense (9M): Rs.56.16 crores (+43.93%)
• Operating profit CAGR (5 years): 5.77%
• ROCE: 23.19%
• Debt to EBITDA ratio: 1.34 times
• Enterprise Value to Capital Employed: 1.7
• Mojo Score: 31.0 (Mojo Grade: Sell, upgraded from Strong Sell)

These figures illustrate a company facing headwinds in profitability and market valuation, despite maintaining operational efficiency and a conservative debt profile.

Technical and Market Sentiment Indicators

The stock’s position below all major moving averages signals a bearish technical outlook. The five consecutive days of decline and the sharp gap down opening today reinforce the downward momentum. While the broader market has shown some resilience, Epigral Ltd’s relative underperformance suggests sector-specific or company-specific factors are influencing investor sentiment.

Given the current market environment and financial data, the stock’s new 52-week low represents a notable milestone in its recent price trajectory.

Limited Period Only. Start at Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Get 71% Off →